Key Highlights
- SEQENS is renowned for its ability to develop and industrialize complex molecules, making it a go-to partner for companies requiring specialized pharmaceutical solutions.
- The company's extensive network of 16 manufacturing plants and 9 R&D centers across Europe, North America, and Asia ensures global reach and operational efficiency.
- With a dedicated team of 350 scientists, engineers, and experts, SEQENS consistently delivers high-quality, tailor-made solutions to meet the unique needs of its clients.
- SEQENS' integrated approach, from research and development to manufacturing, allows it to provide comprehensive and reliable pharmaceutical solutions.
- The company's commitment to innovation and the implementation of the best available technologies positions it as a leader in the pharmaceutical industry.
About SEQENS
SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients, generating a revenue of 1 MM€. The company operates 16 manufacturing plants and 9 R&D centers across Europe, North America, and Asia. With 3,300 employees, including 350 scientists, engineers, and experts, SEQENS develops tailor-made solutions for its customers. The company offers a broad portfolio of active ingredients, pharmaceutical intermediates, and specialty ingredients, focusing on innovation and the implementation of the best available technologies.
SEQENS specializes in developing and industrializing demanding molecules, leveraging its expertise to meet the most challenging requirements of its clients. The company's integrated approach allows it to provide comprehensive solutions, from research and development to manufacturing and delivery. This capability positions SEQENS as a key player in the pharmaceutical industry, offering reliable and high-quality products to its global customer base.
SEQENS' commitment to innovation and quality has established it as a trusted partner in the pharmaceutical sector. The company's extensive network of manufacturing plants and R&D centers ensures that it can efficiently serve markets worldwide, maintaining a strong presence in key regions. Its focus on developing cutting-edge solutions and maintaining high standards makes SEQENS a preferred choice for businesses seeking reliable pharmaceutical ingredients and solutions.
Leadership Team
Tip: The CEO isn't always your best path in. Data Surfer finds the champions and influencers who actually drive purchasing decisions.
Company Facts
| Ownership Private Company |
Office Locations
- North America
Why Contact SEQENS?
B2B professionals should contact SEQENS for access to a broad portfolio of high-quality pharmaceutical ingredients and specialty solutions. The company's expertise in developing and industrializing complex molecules makes it an ideal partner for businesses seeking reliable and innovative pharmaceutical solutions.
Who Should Contact SEQENS for Business?
Sales teams selling pharmaceutical ingredients, recruiters seeking roles in R&D and manufacturing, and partners offering specialized pharmaceutical solutions should reach out to SEQENS.
Categories
- Pharmaceutical Solutions
- Specialty Ingredients
- Pharmaceutical Manufacturing
- Active Ingredients
- Pharmaceutical Intermediates
- R&D Centers
- Manufacturing Plants
- Innovation
- Tailor-made Solutions
- Global Reach
More Pharmaceutical Manufacturing Companies
Frequently Asked Questions
- Who is the CEO of SEQENS?
- Pascal Villemagne is the CEO of the SEQENS group.
- What does SEQENS do?
- SEQENS is an integrated global leader in the development and production of active pharmaceutical ingredients (API), pharmaceutical intermediates, and specialty ingredients for health and personal care.
- How many employees does SEQENS have?
- SEQENS has approximately 3,300 total employees.
- Where is SEQENS headquartered?
- The company is headquartered in Écully, France, at 21 Chemin de la Sauvegarde.
- What industry is SEQENS in?
- SEQENS operates in Pharmaceutical Manufacturing, Specialty Ingredients, Pharmaceutical Solutions.
- When was SEQENS founded?
- SEQENS was founded in 2003.
- Is SEQENS still active?
- Yes, SEQENS was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
- How do I sell to SEQENS?
- Research SEQENS's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.
Ready to Sell to SEQENS?
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Backed by startup programs from
Connect with SEQENS